This document provides an overview of Avedro, the world leader in corneal remodeling. Key points include: - Avedro has developed the first and only FDA-approved corneal cross-linking platform for treating keratoconus and corneal ectasia. They have installed 1500 systems and performed 250,000 treatments. - Their 2017 plans are to expand into keratoconus and refractive markets, drive toward reimbursement, and conduct 14 clinical studies on epi-on procedures and refractive applications. - They have a proven cross-linking mechanism of action that strengthens the cornea to stabilize keratoconus and ectasia. Their PiXL technique allows for non-invasive zonal strengthening to induce corneal

1. The World Leader in Corneal Remodeling

2. Corporate Overview
Achievements 2017 Plan
• First in Class Corneal Remodeling Platform
• The Only FDA Approved Cross-linking
• Commercial
• 1500 Systems
• 250,000 Treatments
• Expand Keratoconus and Refractive Markets
• Driving Towards Reimbursement
• 14 Clinical Studies
• Epi-On Procedures
• Refractive Applications

3. Corneal Remodeling with Cross-linking:
Primary Indications
Refractive CorrectionKeratoconus
Treat underlying
disease state
Eliminate the need for
glasses or contacts
KXL
Uniformly strengthen corneal
stroma to stabilize
PiXL
Selectively strengthen the
corneal stroma to reshape
IndicationSolution

4. Proven Mechanism of Action

5. Keratoconus
• Progressive corneal irregularity due to
underlying stromal weakness
• Number one cause for corneal transplants
• Published data from 1986 indicates
302,000 eyes1
• Newer diagnostic methods enable earlier
and more accurate diagnosis
1. Kennedy RH, Bourne WM, Dyer JA. A 48-year clinical and
epidemiological study of keratoconus. Am J Ophthalmol. 1986;101:267–73
Normal Cornea
Keratoconus

6. -0.9
-0.6
-0.3
0
0.3
0.6
0.9
KC CXL KC Control
n=175
p<0.0001
-0.9
-0.6
-0.3
0
0.3
0.6
0.9
-1.5
-1
-0.5
0
0.5
1
1.5
2
KC CXL KC Control
2.6D
Difference
n=205
p<0.0001
-2.0
-1.5
-1.0
-0.5
0
0.5
1.0
1.5
Progressive Keratoconus Corneal Ectasia
The Only FDA Approved Treatment for
Progressive Keratoconus and Corneal Ectasia
1.4D
Difference

7. Reimbursement
• Medically indicated treatment for orphan
disease (progressive keratoconus)
• Not an elective procedure
• Hundreds of patients awaiting
reimbursement to get treatment
• Set up reimbursement hub: ARCH

8. Superior Outcomes with Oxygen
UVA Light
(365nm)
+
Corneal
Collagen
Crosslinks (Covalent Bonds)
Riboflavin
+
Oxygen is critical to the underlying photochemical kinetic mechanisms of crosslinking
Oxygen
O2

9. PiXL: Photorefractive Intrastromal Cross-linking
Non-Invasive Zonal Strengthening to Induce Corneal Remodeling

10. European Epi-On PiXL Studies:
Preliminary Clinical Results
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Baseline 1 Month
DecimalAcuity
Mean Distance UCVA (n=13)
20/100
20/25

11. Refractive Correction
Low Myopia
• Largest population under 45 years
of age needing glasses
• Glasses and Contact Lens users
Presbyopia
• Loss of near focus
• Everyone above 45 years of Age
Potential
Future Indications
• Hyperopia
• Astigmatism
• Post IOL Correction
• Customized KC

12. - 0.75 to -1.25D >27M eyes
- 0.75 to -2.75D >62M eyes
US PiXL Opportunity
Market by Refractive Error

14. Corporate Overview
Achievements
• First in Class Corneal Remodeling Platform
• The Only FDA Approved Cross-linking
• Commercial
• 1500 Systems
• 250,000 Treatments
2017 Plan
• Expand Keratoconus and Refractive Markets
• Driving Towards Reimbursement
• 14 Clinical Studies
• Epi-On Procedures
• Refractive Applications
Solid Foundation
• Strong Management Team and Advisors
• Strong Investor Syndicate
• Strong Balance Sheet

15. Thank You
Visit Avedro at
Booth #: 637